Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsPOXEL SA announced the completion of enrollment in DESTINY-1, a dose-ranging Phase II trial evaluating PXL065 for the treatment of non-alcoholic steatohepatitis (NASH).
[POXEL SA]
Home Newsletters Hepatic Cell News Poxel Completes Enrollment in Phase II NASH Trial for PXL065 (DESTINY-1) in...
